1. Home
  2. ACRS vs HEQ Comparison

ACRS vs HEQ Comparison

Compare ACRS & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • HEQ
  • Stock Information
  • Founded
  • ACRS 2012
  • HEQ 2011
  • Country
  • ACRS United States
  • HEQ United States
  • Employees
  • ACRS N/A
  • HEQ N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • HEQ Investment Managers
  • Sector
  • ACRS Health Care
  • HEQ Finance
  • Exchange
  • ACRS Nasdaq
  • HEQ Nasdaq
  • Market Cap
  • ACRS 165.7M
  • HEQ 127.0M
  • IPO Year
  • ACRS 2015
  • HEQ N/A
  • Fundamental
  • Price
  • ACRS $1.43
  • HEQ $10.67
  • Analyst Decision
  • ACRS Strong Buy
  • HEQ
  • Analyst Count
  • ACRS 8
  • HEQ 0
  • Target Price
  • ACRS $9.71
  • HEQ N/A
  • AVG Volume (30 Days)
  • ACRS 1.3M
  • HEQ 43.1K
  • Earning Date
  • ACRS 08-06-2025
  • HEQ 01-01-0001
  • Dividend Yield
  • ACRS N/A
  • HEQ 9.78%
  • EPS Growth
  • ACRS N/A
  • HEQ N/A
  • EPS
  • ACRS N/A
  • HEQ N/A
  • Revenue
  • ACRS $17,777,000.00
  • HEQ N/A
  • Revenue This Year
  • ACRS N/A
  • HEQ N/A
  • Revenue Next Year
  • ACRS $11.77
  • HEQ N/A
  • P/E Ratio
  • ACRS N/A
  • HEQ N/A
  • Revenue Growth
  • ACRS N/A
  • HEQ N/A
  • 52 Week Low
  • ACRS $1.05
  • HEQ $9.08
  • 52 Week High
  • ACRS $5.17
  • HEQ $11.84
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 51.06
  • HEQ 61.51
  • Support Level
  • ACRS $1.38
  • HEQ $10.45
  • Resistance Level
  • ACRS $1.52
  • HEQ $10.56
  • Average True Range (ATR)
  • ACRS 0.10
  • HEQ 0.09
  • MACD
  • ACRS -0.01
  • HEQ 0.01
  • Stochastic Oscillator
  • ACRS 39.10
  • HEQ 82.33

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: